

PIIL:SEC:PR:2020-21 October 28, 2020

BSE Limited,	National Stock Exchange of India Ltd.
Corporate Relationship Deptt.	Exchange Plaza, Plot No.C/1,
25 <sup>th</sup> Floor, New Trading Ring	G-Block, Bandra Kurla Complex,
Rotunda Building	Bandra (East),
P.J. Towers, Dalal Street,	Mumbai - 400 051
MUMBAI - 400 001	
	Code No. PIIND
Code No.523642	

Dear Sir,

Sub: Press Release on Performance of the Company for the quarter and half year ended September 30, 2020.

We are enclosing herewith a copy of Press Release dated October 28, 2020 on the performance of the Company for the quarter and half year ended September 30, 2020.

You are requested to take same on record.

Gurgaon

Thanking you,

Yours faithfully, For **PI Industries Limited** tries

Naresh Kapoor Company Secretary

Encl: As above.

PI Industries Ltd.



# Business Performance Update Q2 FY 2020-21

Certain statements made in this presentation may not be based on historical information or facts and may be "forward looking statements," including those relating to general business plans and strategy of PI Industries Limited ("PIIL"), its future outlook and growth prospects, and future developments in its businesses and its competitive and regulatory environment. Actual results may differ materially from these forward-looking statements due to a number of factors, including future changes or developments in PIIL's business, its competitive environment, its ability to implement its strategies and initiatives and respond to technological changes and political, economic, regulatory and social conditions in India. This presentation does not constitute a prospectus, offering circular or offering memorandum or an offer, or a solicitation of any offer, to purchase or sell, any shares and should not be considered as a recommendation that any investor should subscribe for or purchase any of PIIL's shares. Neither this presentation nor any other documentation or information (or any part thereof) delivered or supplied under or in relation to the shares shall be deemed to constitute an offer of or an invitation by or on behalf of PIIL.

PIIL, as such, makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information or opinions contained herein. The information contained in this presentation, unless otherwise specified is only current as of the date of this presentation. PIIL assumes no responsibility to publicly amend, modify or revise any forward looking statements, on the basis of any subsequent development, information or events, or otherwise. Unless otherwise stated in this document, the information contained herein is based on management information and estimates. The information contained herein is subject to change without notice and past performance is not indicative of future results. PIIL may alter, modify or otherwise change in any manner the content of this presentation, without obligation to notify any person of such revision or changes. This presentation may not be copied and disseminated in any manner.

THE INFORMATION PRESENTED HERE IS NOT AN OFFER OR SOLICITATION OF ANY OFFER TO PURCHASE OR SELL ANY EQUITY SHARES OR ANY OTHER SECURITY OF PI INDUSTRIES LTD.

#### CDR India

Nishid Solanki <u>nishid@cdr-india.com</u> Siddharth Rangnekar <u>siddharth@cdr-india.com</u>

Tel: +91 22 6645 1221 /1209 Fax: +9122 6645 1213








#### PI Industries Limited

Rajnish Sarna <u>r.sarna@piind.com</u> Rajiv Batra <u>rajiv.batra@piind.com</u>

Tel: +91 124 6790000 Fax: +91 124 4081247

### **Q2'FY21... out-performance continues** Revenue growth by 28%, EBITDA up by 45%.. PAT by 77%


#### CONSOLIDATED



- Inspired by Science
- Covid-19 disruption to operations and movement of goods impact in a limited manner with all manufacturing facilities operational and capacity utilisation building back to pre-Covid levels
- ✓ Q2 Exports increase ~25% YoY with proactive raw material inventory management and precise capacity planning, scaling up exports. Demand for key commercialised molecules remains strong.
- ✓ Domestic Revenues increase by 33%, with additional contribution from Isagro brand sales and moderate growth in the domestic segment.
- ✓ 171 basis increase in gross margin due to change in business mix of Export, Domestic and Isagro share
- ✓ Net Profit surge with higher momentum in topline , depreciation inline with capacities added increased from 32 Cr to 43 Cr.

### H1'FY21 witnessed impressive growth Revenue growth by 33%, EBITDA up by 48%.. PAT by 62%

#### CONSOLIDATED



- Limited Covid-19 disruption to operations and movement of goods with all manufacturing facilities operational and capacity utilisation building back to pre-Covid levels
- ✓ H1 Exports increased ~24% YoY despite disrupted global supply chain, proactive raw material inventory management and precise capacity planning scaling up exports. Demand for key commercialised molecules remains strong.
- ✓ Domestic up by 54%, inclusive of Isagro brand sales with and robust momentum in the domestic segment on planned brand positioning.
- ✓ Net Profit surge with higher momentum in topline , depreciation inline with capacities added increased from 61 Cr to 86 Cr.



## **Balance Sheet position remained strong**

#### **Efficient W/C management helping transition uncertain times..**

	/ 0	
(Rs in Cr.)s	<b>SEP 20</b>	<b>SEP 19</b>
Shareholders' Funds	5,013.7	2,478.9
Non Current Liabilities	579.2	54.8
Long-term borrowings	416.0	0.1
Deferred Tax Liabilities (net)	89.0	-
Other long-term liabilities	58.2	22.1
Long-term provisions	16.0	32.6
Current Liabilities	1,431.0	1,134.3
Trade payables	912.9	697.3
Other current liabilities	472.4	423.2
Short-term provisions	45.7	13.8
TOTAL	7,023.9	3,668.0
Non Current Asset	2,502.9	1,765.4
Net Fixed Asset	2,149.2	1,680.7
Good Will	82.8	-
Non-current investments	22.8	17.2
Long term Loans & advances	6.0	2.8
Other Assets	242.1	64.7
Current Asset	4,521.0	1,902.6
Inventories	990.3	691.0
Trade receivables	753.6	714.7
Cash, Bank & Investments	2,393.4	190.2
Short-term loans and advance	37.7	29.9
Other assets	346.0	276.8
TOTAL	7,023.9	3,668.0
KEY RATIOS (ANNUNALISED)		
Net sales to Fixed assets	2.06	1.98
Net Sales to Working capital	5.34	4.69
Net Sales to Inventory	4.48	4.81
Current ratio	3.16	1.68
Debt Equity ratio	0.08	0.00



- Net working capital to sales improved from 4.69 to 5.34 as at Sep 20 despite Covid-19 disruption and resultant liquidity challenges in the markets.
- Increase in operating cash flow helping fund continued strategic initiatives
- Non Current Other assets higher due to long term deposits of Rs. 191 Crs
- Increased inventory levels in line with expected growth and to ensure continuity of operations amid Covid-19 uncertainties.
- Net sales to fixed Assets improved to 2.06 Vs. 1.98 PY
- QIP funds invested with SLR philosophy while final deployment aligned with PI's longer term growth strategy is underway...

# **Key operational highlights Q2'FY21**

#### Planned progress on strategic initiatives for sustained growth..



	Steady growth of Domestic Agri Input	<ul> <li>Highest ever POG of Nominee Gold. Successful execution of tank mix solutions to ensure broader weed coverage</li> <li>Establishment of Osheen in cotton preventive segment with very positive momentum in rice</li> <li>Two products launched – Londax Power (insecticide) and Shield (fungicide)</li> <li>Leveraged Isagro's strength to augment PI's horticulture focussed strategy</li> </ul>
50000	Expansion of CSM Exports	<ul> <li>All MPPs are operational. One MPP under construction to be commissioned next year</li> <li>Integration of Isagro facilities with PI with an aim to maximize synergies and capacity utilisation</li> <li>40+ products at various stages of R&amp;D pipeline</li> </ul>
	Digitalisation and process improvement	<ul> <li>Deploying analytical tools to augment the productivity of plants</li> <li>Digital campaigns organized at different levels for product launches and engage customers</li> <li>Good adoption of PI Mitra enabling PI to track real time liquidation of products</li> </ul>
	IPR Creation, Foraying into Pharma	<ul> <li>18 new patent application filed during H1'FY21 including intermediaries of Covid-19. One of the top few companies in India in filing patents.</li> <li>Continue to supply Pharma intermediates on commercial scale with more than 10+ pharma products at various development stages in R&amp;D</li> </ul>
		<ul> <li>Launched Percipio e-Learning platform to boost employee skills</li> </ul>
$(\mathbf{I})$	HR Initiatives	<ul> <li>Despite Covid-19 challenges, top and next generations leadership trainings in full swing</li> <li>Ground work ready for new onboarding program 'Project Aagman' to improve Talent Mgmt</li> </ul>

# **Business outlook remains robust..**

Focused progress on strategic initiatives to continue while navigating through pandemic Original growth guideline is maintained...



Focus on Demand generation	<ul> <li>Good outlook for Rabi crops as reservoirs are full</li> <li>Continue to have robust demand for branded products to drive growth</li> <li>High growth expected from PI wheat herbicide portfolio. Spray solutions to augment this growth</li> </ul>
CSM Exports to continue growth momentum	<ul> <li>All global customers giving positive commentary; no change in demand forecast</li> <li>Volume Scale up expected for some of the products commercialized in last 1-2 years.</li> <li>Promising products in R&amp;D pipeline, gradual ramp up in progress.</li> <li>Order book remained robust @ ~US\$ 1.5 Bn; high visibility of sustainable growth over 3-5 yrs</li> </ul>
Strategic direction and priorities remain intact while carefully transitioning thru Covid-19 uncertainties	<ul> <li>Pursuing inorganic growth opportunities to diversify into adjacencies, widen technology portfolio and de-risk operations</li> <li>Build new IP building for deepening our technological capabilities, de-risking current operations and opening up newer opportunities</li> <li>Actively evaluating few pharma assets and working with global consulting firm for crystallisation and successfully implementing strategic road map of diversification</li> </ul>

#### Confident of achieving 20% plus growth in FY21 and resolutely progressing on that path

## **Our Vision & Values..**





"Building on the foundation of trust, we shall be at the forefront of science-led opportunities by delivering innovative solutions."

### VALUES

TRUST Like the earth, we are dependable. We work with integrity of purpose, honesty in action and fairness in all our dealings




INNOVATION Enlivening, like the air, in the constant quest for the horizon, the never-ending search for a better, newer way to do things; Innovation for us, is a way of life

#### ADAPTABILITY Adaptive, like water, we are constantly transforming ourselves. Being nimble footed, we are highly responsive to change

# Strong focus on customer needs and continuous innovation






PI EXTERNAL Domestic Business – Brands

Evaluation & Trials Regulatory services Marketing & & Registrations Distribution

## **Differentiated domestic distribution**

#### Driven by brands and market reach

Inspired by Science



Development

CA

Scale-up Manufact

# Custom Synthesis & Manufacturing – Our vision




#### **OUR FOCUS**

am	OUR FOCUS			
Imagine stives	Partner of Choice	Solutions		
Adda Electronics Low - Mid volume Process technology Complex chemistry IP (generation / protection) High Potential PI as 1 or 1 of 2-3 sources Customer as innovators Po.	<ul> <li>Who</li> <li>Niche player / boutique industry – leading supplier</li> <li>How</li> <li>Longevity of meaningful engagement</li> <li>A marriage of competent equals</li> <li>Consultative solution rendering &amp; outsourcing process</li> <li>Reliability of services</li> </ul>	<ul> <li>Service Lines</li> <li>Characterized by</li> <li>Process Development</li> <li>Analytical Research &amp; Services</li> <li>Process Development</li> <li>Regiatability &amp; predictability</li> <li>Repeatability</li> <li>Supply chain customer</li> <li>Supply chain customer</li> <li>End applications</li> </ul>		
Pharma Pharma FINE HEM	PI has all that is required to be the "Partner of Choice"	On-patent       On-patent         growing       mature         Pre-launch       "         """"""""""""""""""""""""""""""""""""		

**Inspired by Science** 

#### **PI EXTERNAL**

### Global tailwinds offering opportunities for aggressive, multi-pronged growth strategy



Prudent financial management in place to ensure that long term shareholder value creation remains at the heart of the strategy...



Thank you

PI Industries Ltd. Corporate Off: 5th Floor, Vipul Square, B Block, Sushant Lok, Phase - 1, Gurgaon - 122009 (Har), India; Tel: +91 124 6790000, Fax: +91 124 4081247. Regd. Off: Udaisagar Road, Udaipur - 313001; Tel: +91 294 2491451-5, Fax: +91 294 2491946. www.piindustries.com